001484630 000__ 04818cam\\2200541\i\4500
001484630 001__ 1484630
001484630 003__ OCoLC
001484630 005__ 20240117003331.0
001484630 006__ m\\\\\o\\d\\\\\\\\
001484630 007__ cr\cn\nnnunnun
001484630 008__ 231208s2023\\\\sz\a\\\\o\\\\\000\0\eng\d
001484630 019__ $$a1411349283$$a1411788050
001484630 020__ $$a9783031316944$$q(electronic bk.)
001484630 020__ $$a3031316940$$q(electronic bk.)
001484630 020__ $$z9783031316937
001484630 020__ $$z3031316932
001484630 0247_ $$a10.1007/978-3-031-31694-4$$2doi
001484630 035__ $$aSP(OCoLC)1412515245
001484630 040__ $$aGW5XE$$beng$$erda$$epn$$cGW5XE$$dOCLCO$$dYDX$$dOCLKB
001484630 049__ $$aISEA
001484630 050_4 $$aRS199.5
001484630 08204 $$a615/.6$$223/eng/20231208
001484630 24500 $$aExploring drug delivery to the peritoneum /$$cRanjita Shegokar, editor.
001484630 264_1 $$aCham :$$bSpringer,$$c[2023]
001484630 264_4 $$c©2023
001484630 300__ $$a1 online resource (x, 242 pages) :$$billustrations (chiefly color)
001484630 336__ $$atext$$btxt$$2rdacontent
001484630 337__ $$acomputer$$bc$$2rdamedia
001484630 338__ $$aonline resource$$bcr$$2rdacarrier
001484630 5050_ $$aChapter 1: Peritoneal Organ-Anatomical and Physiological Considerations -- Chapter 2: drug delivery platforms for intra-peritoneal delivery focusing primarily on need, delivery systems, clinical progress, market and regulatory aspects -- Chapter 3: Liposomes and Lipid Nanoparticles as Peritoneal Drug Delivery Systems -- Chapter 4: Nano and micro/medicines for intraperitoneal therapy in ovarian cancer: critical overview and focus on pharmaceutical manufacturing under cGMP -- Chapter 5: Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC): Promising Strides from India -- Chapter 6: HIPEC: Concept and Fundamentals in Colorectal Cáncer Peritoneal Mestatasis Treatment -- Chapter 7: Peritoneal Implants and Drug Delivery -- Chapter 8: Importance of Computational Models in Development of Intrapertitoneal Administration based Drug Delivery Systems for Solid Tumors -- Chapter 9: Drug Delivery Systems for peritonium : current status and Future perspectives -- Chapter 10: Exploring the Intraperitoneal Route in a New Way for Preclinical Testing.
001484630 506__ $$aAccess limited to authorized users.
001484630 520__ $$aThe Peritoneal cavity (PC) is the key metastatic site for intra-abdominal malignancies (e.g., GI tract and rectal cancer). PC sites can be used to target several other diseases where lymphatic drug delivery is desired without dumping large amounts of the drug. Until recently, it was thought that treatment with curative intent was impossible but that was challenged by the introduction of cytoreductive surgery (CRS), heated intraperitoneal chemotherapy (HIPEC), and PIPAC (pressurized intraperitoneal aerosol chemotherapy). Recently, a growing number of preclinical and clinical studies advocate intraperitoneal (IP) chemotherapy as an alternative post-operative therapy for cancer. Although their effectiveness has been proven both experimentally and clinically, there is still little understanding of the role of drug delivery systems in targeting drugs in the intraperitoneal (IP) cavity. There are two main challenges posed to such therapies 1) the complexity of IP cavity and 2) the drug transport dynamics e.g., the residence time of small molecular weight drugs, the fate of delivery systems (both nano and micro), etc. The present book is a link between pharmaceutical scientists (drug formulators), clinicians, and toxicologists. This book also provides a new perspective to researchers to divert or guide their research in an optimal way. Exploring Drug Delivery to the Peritoneum serves as a platform for upcoming technologies especially in the medical devices sector to face up and show potential in delivering drugs to IP cavity. It is a chance for commercial partners like insurance companies and the pharma industry to explore the old administration route in a new way. .
001484630 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed December 8, 2023).
001484630 650_0 $$aDrug delivery systems.
001484630 650_0 $$aPeritoneum.
001484630 650_6 $$aSystèmes d'administration de médicaments.
001484630 650_6 $$aPéritoine.
001484630 655_0 $$aElectronic books.
001484630 7001_ $$aShegokar, Ranjita,$$eeditor.
001484630 77608 $$iPrint version: $$z3031316932$$z9783031316937$$w(OCoLC)1374106819
001484630 852__ $$bebk
001484630 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-031-31694-4$$zOnline Access$$91397441.1
001484630 909CO $$ooai:library.usi.edu:1484630$$pGLOBAL_SET
001484630 980__ $$aBIB
001484630 980__ $$aEBOOK
001484630 982__ $$aEbook
001484630 983__ $$aOnline
001484630 994__ $$a92$$bISE